2Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
5Cho J H, Cheong J Y,Kang J K,et al.Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B pa- tients.Korean J Hepatol ,2008 , 14 ( 1 ) :58-66.
6Lampertico P,Vigano M,Manenti E, et al.Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine -resistant hepatitis B patients.Gastroenterology, 2007,133 (5): 1445-1451.
7Rapti I,Dimou E, Mitsoula P, et al.Adding-on wersus swithing- to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B patients.Hepatology, 2007,45 ( 2 ) : 307-313.
8Lampertico P,Vigano M,Manenti E,et al.Adefovir rapidly sup- presses hepatitis B in HBeAg-negative patients developing genotypie resistance to lamivudine. Hepatology, 2005,42 (6) : 1414-1419.
9Yuen MF,Fong DY,Wong DK,et al. Hepatitis B vires DNA levels at week 4 of lamivudine treatment predict the 5-year ide- al response. Hepatology, 2007,46(6) : 1695-1703.
10Madan K,Batra Y,Jha JK,et al.Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.Trop Gastroenterol, 2008,29(2) : 59-61.
